Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of the availability of prescription medication used to treat ADHD.

We are aware of disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD). Some issues have now been resolved. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. These issues are expected to resolve by end December 2023.

We understand how frustrating and distressing medicine shortages can be and we want to assure patients that we are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.

We have issued communications to the National Health Service to advise healthcare professionals on management of patients whilst there continue to be disruptions to supplies. Patients are advised to speak to their clinician regarding any concerns they have and to discuss the suitability of treatment with alternative medicines.